Medifast Stock Price, News & Analysis

Medifast (NYSE: MED) reported a 15.0% increase in revenue to $453.3 million for Q2 2022, driven by a 14.9% rise in active earning OPTAVIA Coaches to 68,000. However, net income decreased 16.7% to $39.1 million, leading to an EPS of $3.42, down 13.6%. The company announced a $100 million accelerated share repurchase program and plans to pay a quarterly cash dividend of $1.64 per share. Due to macroeconomic pressures, Medifast revised its full-year revenue guidance down to $1.58 billion - $1.66 billion and EPS to $12.70 - $14.10.

Medifast (NYSE: MED) hosted its annual OPTAVIA Convention from July 21-23, 2022, in Atlanta, attracting over 17,000 attendees, marking the largest event to date. The company reported significant growth, becoming the top weight loss program in the U.S. by revenue in 2021. Medifast aims to expand its presence in the $230 billion health market, with CEO Dan Chard stating they've served more clients than ever. The event included keynote speakers and raised over $90,000 for charity, emphasizing their commitment to community and health transformation.

Medifast (NYSE: MED) has expanded its Scientific Advisory Board, adding Dr. Nikhil Dhurandhar, Dr. Graham Thomas, and Dr. Jessica Unick. This brings the board to seven experts, enhancing its capacity to provide evidence-based insights in health and wellness. Dr. Dhurandhar specializes in lifestyle interventions for obesity, while Dr. Thomas focuses on technology in health behavior research. Dr. Unick studies behavioral intervention adaptions for weight loss. This expansion aligns with Medifast's commitment to high-quality, consumer-centric innovations as it targets a $230 billion health and wellness industry.

Medifast (NYSE: MED) released survey findings indicating that 70% of U.S. adults prioritize health, yet 50% struggle to do so, mainly due to lack of time and support. Only 28% of those on a traditional diet maintain it long-term, while 79% revert to previous habits. The survey also revealed that 67% believe more support would aid in reaching health goals. The COVID-19 pandemic has altered health priorities for 61% of respondents, underscoring the demand for holistic health solutions.

Medifast, Inc. (NYSE: MED) declared a $1.64 quarterly cash dividend for stockholders, payable on August 8, 2022, to those on record by June 28, 2022. The company is recognized as a leader in the weight management industry, impacting over 2 million lives with its OPTAVIA® program. The decision to pay future dividends will depend on the Board's discretion, considering relevant factors. Medifast aims to maintain quarterly dividend payments, signaling confidence in its financial stability and commitment to its shareholders.

Medifast, Inc. (NYSE: MED) announced that CEO Dan Chard and CFO Jim Maloney will engage with investors at the Jefferies Consumer Conference on June 20-22, 2022, in Nantucket, MA. A webcast of the session will be available on June 20, 2022, at 8:00am ET, accessible through Medifast's investor relations website. The company, known for its health and wellness community, continues to lead the U.S. weight management industry, serving over 2 million people through its OPTAVIA platform.

Medifast (NYSE: MED) announced a $100 million accelerated share repurchase (ASR) program with JPMorgan Chase to buy back approximately 600,000 shares, representing 5% of its outstanding stock. This move aims to enhance shareholder value and reflects the company's confidence in its growth strategy. Medifast plans to use available cash and borrowings for the ASR, with a remaining 1.4 million shares authorized for repurchase. The final settlement of the ASR will occur in Q3 2022, as the company continues to generate strong cash flow and invests in technology and product innovation.

Medifast has inaugurated the Medifast Product Innovation Center in Baltimore on May 10, 2022, to accelerate innovation and support its rapid growth in the $230 billion health and wellness market. The facility includes advanced office, lab, and pilot plant spaces, aimed at enhancing R&D, packaging engineering, and quality assurance. CEO Dan Chard highlighted that the company's revenue has doubled twice in five years, emphasizing the center's role in developing scientifically-backed products for its OPTAVIA program and expanding into new health segments.

Medifast, Inc. (NYSE: MED) reported a remarkable 22.6% increase in revenue to $417.6 million for Q1 2022, driven by a 21.7% rise in active OPTAVIA Coaches to 63,900. Net income grew 1.7% to $41.8 million, with earnings per share (EPS) at $3.59, a 3.8% increase. The company raised its annual revenue guidance to between $1.78 billion and $1.84 billion and adjusted full-year EPS expectations to $14.60 to $16.05. Despite growing expenses and lower gross profit margin, Medifast’s strong balance sheet and operational metrics indicate robust business health.